Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.


Read More

President Donald Trump

President Donald Trump delivers remarks during a campaign rally at Lubbock Memorial Civic Center on Oct. 27, 2026, in Lubbock, Texas. With one week until the midterm elections, President Trump was pushing to boost support for incumbent Texas Gov. Greg Abbott and Republican U.S. Senate candidate, Texas Attorney General Ken Paxton.

(Getty Images)

Trump doesn’t care about the midterms. You should

Despite how ubiquitous, prolix, and attention-seeking as he is, sometimes it’s still hard to know what makes President Trump do the things he does.

Why, for example, is he so fixated on “acquiring” places like Greenland? Why is he obsessed with renaming things and changing the maps? Shouldn’t he be too busy presidenting to care about whatever Bill Maher said about him? And what the hell is with all the butt talk lately?

Keep ReadingShow less
woman enters a building to vote
a group of people outside a building

Political Accountability Begins Before Election Day

In a response video circulating on September 22, Brandon Herrera, the Republican nominee in Texas’s 23rd Congressional District, described his remarks about mothers and children as “a bit crass” but said “the sentiment stands”. His response renewed a question that extends beyond one candidate: what responsibility do parties bear before voters make their choice?

Elections are supposed to make politicians accountable. Candidates ask voters to judge their records, their positions, and their conduct, and voters ultimately decide who will represent them. But that familiar picture of democracy leaves out an important part of the process: much of the work shaping the general-election choice happens earlier. Parties recruit candidates, political organizations support them, donors help finance them, and influential political figures give them credibility. Herrera’s candidacy offers a revealing example of how that process works.

Keep ReadingShow less
Nigeria flag, elections, ballot box, casting vote.

Nigeria flag, elections, ballot box, casting vote.

Getty Images

As Nigeria Prepares to Vote, Years of U.S. Democracy Support Face a New Test

For years, American institutions helped Nigerian civic groups train election observers, track political violence and challenge false information. As Nigeria approaches its 2027 elections, the organizations that developed that expertise face a different question: how much of the work can they sustain with less financial and technical support?

Dauda Garuba, director of the Centre for Democracy and Development (CDD West Africa), sees the change as part of a broader shift in American foreign policy. But he also believes it invites an uncomfortable assessment of Nigeria’s elections.

Keep ReadingShow less

Taxpayer-Funded, Closed to Millions: The Growing Push to Reform Kentucky’s Primaries

More than half of America’s military veterans identify as independents, not Democrats or Republicans. Yet in many states with closed primary systems, those voters are barred from participating in taxpayer-funded primary elections. Because veterans swear an oath to defend the Constitution, not a political party, a growing coalition of veteran-led organizations is advocating for open primaries and other electoral reforms designed to expand voter participation and strengthen representative democracy.

In Kentucky, veterans have emerged as leading voices in a nonpartisan campaign to open the Commonwealth’s closed primary system. Their efforts come as the state's electorate shifts: independent voters are the fastest-growing segment of registered voters.

Keep ReadingShow less